Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 100 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Celcuity Inc | CELC | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 16.30 | 07:03:04 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.30 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 1 | 100 | - | 8.389 - 22.188 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:03:01 | formt | 100 | US$ 16.30 | USD |
Celcuity Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 394.51M | 24.20M | - | 0 | -63.78M | -2.64 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Celcuity News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CELC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.7397 | 16.7945 | 14.63 | 15.99 | 335,954 | -0.4397 | -2.63% |
| 1 Month | 20.40 | 20.885 | 14.63 | 17.31 | 204,335 | -4.10 | -20.10% |
| 3 Months | 14.83 | 22.188 | 13.74 | 17.64 | 245,276 | 1.47 | 9.91% |
| 6 Months | 10.04 | 22.188 | 9.99 | 16.47 | 182,486 | 6.26 | 62.35% |
| 1 Year | 9.70 | 22.188 | 8.389 | 14.65 | 129,841 | 6.60 | 68.04% |
| 3 Years | 28.50 | 33.01 | 4.81 | 14.55 | 85,668 | -12.20 | -42.81% |
| 5 Years | 21.50 | 33.01 | 4.03 | 16.39 | 74,929 | -5.20 | -24.19% |
Celcuity Description
| Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). |
